Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04459117
Other study ID # C19-29
Secondary ID 2019-004297-26
Status Active, not recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date October 29, 2020
Est. completion date July 2024

Study information

Verified date April 2024
Source Institut National de la Santé Et de la Recherche Médicale, France
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

TREOCAPA is a Phase II/III European Multicentre study concerning the prophylactic treatment by Acetaminophen of extremely preterm infant during the first five days after birth. The Phase II is a dose finding phase in order to assess the minimum effective dose regimen of acetaminophen for the closure of PDA for neonates with a gestational age less than 27 weeks This part of the study will be conducted in 11 NICUs, in 4 countries (France, UK, Finland and Denmark). The Phase III is The phase III is a randomized, multicenter, double-blind, placebo-controlled superiority trial, two arms in a 1:1 ratio, evaluating an increasing of 10% of the percentage of survival without severe morbidity at 36 weeks of post menstrual age. In the intervention arm, 20 mg/kg followed by 7.5 mg/kg quarter in die (QID) will be administered to the 27-28 weeks gestational age group (dosage confirmed through PK/PD data analysis from the previous Finnian study) and the dosage selected after the conclusion of the Phase II will be administered to the 23-26 weeks gestational age group. A group sequential design, with a total of 3 analyses (2 interim analyses and a final) and the O'Brien-Fleming alpha spending function is chosen for the trial. At the same time, a Bayesian sequential analysis is planned for safety endpoints


Description:

The Phase II will be conducted in 11 NICUs, in 4 countries (France, UK, Finland and Denmark). The estimated recruitment period is 6 months to enroll 30 preterm infants of 23-26 weeks of gestation. Four different loading/maintenance doses will be tested. The first level will be 20 mg/kg followed by 7.5 mg/kg quarter in die (QID) which correspond to the dosage selected for neonates with a PMA ≥27 weeks in the phase III according to data from Finland (Härkin, J Pediatr. 2016). The 2nd, 3rd and 4th level doses will stand for 25%, 50%, and 75% increase of the first level: - 20 mg/kg loading dose then 7.5 mg/kg/6hours during 5 days (total = 20 doses) - 25 mg/kg loading dose then 10 mg/kg/6hours during 5 days (total = 20 doses) - 30 mg/kg loading dose then 12 mg/kg/6hours during 5 days (total = 20 doses) - 35 mg/kg loading dose then 15 mg/kg/6hours during 5 days (total = 20 doses) The first cohort of patients will be treated at the lowest starting dose level. Both, the Data Safety Monitoring Board (DSMB) and the statistician will be informed about the therapeutic response observed and the safety of treatment. The statistician will use these data for re-estimation of the posterior probability of success. The DSMB will be then informed about the statistical recommendation for the next dose level to use in the next cohort of 3 patients. The decision to go up, go down or stay on the same dose level will remain to the DSMB who will be free to follow or not the statistical recommendation. Dose escalation will not increase by more than one level, although dose de-escalations could be large. At inclusion, basic data (pregnancy, blood results, birth and transfer) are recorded. After inclusion, systemic arterial pressure is measured before administration of the first dose of acetaminophen. Then the preterm infant receives a loading dose of acetaminophen. A first blood sample is collected just after end of loading dose infusion (T15min) to analyze Acetaminophen plasma level (0.2mL) ans ALT/AST (0.1ml to 0.3ml, according to local biological laboratory). Each 6 hours during the first 5 days of life, each preterm infant receives a perfusion of acetaminophen, so 20 doses are administered in total. Systemic arterial pressure is measured at 30', 60', 90', 120' after each dose. Each day, a cardiac echography is performed. After Dose 10, a second blood sample (0.3 ml to 0.5 ml according to local biological laboratory) is collected to analyze acetaminophen plasma level and ALAT & ASAT. During visit 1 at day 3, eCRF is completed for period Day 1 to Day 3. A few "bottom of blood tubes" sampled for routine care will be kept for others acetaminophen plasma level analysis. This will be done in centres where this procedure is possible.After the last dose of acetaminophen, a blood sample of 0,3 to 0.5ml (ideally 6 hours after the start of last infusion) is collected to analyze ALAT & ASAT and Acetaminophen plasma level (0.2 ml). During visit 2 at Day 5, eCRF is completed for period Day 4 to Day 5. A cardiac echography is performed after the last dose of acetaminophen. Data from a cerebral echography performed in routine care during the first week after the first dose will be recorded. During Visit 3, at Day 7, CRF is completed, and the information about primary outcome (closure or not of the Ductus Arterosus) is sent by email to experts of the research unit EA 7323 " Evaluation of Therapeutics and pharmacology in perinatality and pediatrics ", University of Paris-Descartes, Paris, France. The Phase III is a pragmatic trial. At inclusion, basic data (pregnancy, blood results, birth and transfert) are recorded. After inclusion, randomization is performed. After randomization, each infant receives a loading dose of acetaminophen or placebo before 12 hours of life. After the loading dose of Acetaminophen, a supplement of 0.1 to 0.3 ml of blood will be collected, as supplement of a blood sample performed in routine care for AST/ALT analysis. Each 6 hours during the first 5 days of life, each preterm infant receives a perfusion of placebo or acetaminophen, so 20 doses are administered in total. After the dose 10 of Acetaminophen, a supplement of 0.1 to 0.3 ml of blood will be collected as supplement of a blood sample performed in routine care for AST/ALT analysis. Few "bottom of blood tubes" sampled for routine care will be kept for acetaminophen plasma level analysis in 50 first preterm infants (25 in each gestational age group) chosen hospitalized in the NICUs participating to Phase II. This will be done in NICUs where this procedure is possible). During visit 1 at Day 7, data describing baby care are recording day by day from Day 0 to Day 7. Around Day 7 (between Day6 and Day 10) one cardiac echography is performed. During visit 2 at Day 28, a review of different cares received by the baby between Day 8 and Day 28 is recorded. Data from a cerebral echography performed in routine care, before 36 weeks of postmenstrual age or before discharge if it occurs before will be recorded in the eCRF. Result of the last ophthalmological examination performed in routine care before 36 weeks of postmenstrual age or before discharge if it occurs before, should be noted in the eCRF. During visit 3 at 36 weeks of postmenstrual age or at first discharge home, whatever comes first, a review of mobidity (BPD, cerebral lesions, retinopathy, necrotizing enterocolitis) is performed to complete the primary endpoint. At the end of hospitalization, clinical data at discharge are recorded


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 824
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 23 Weeks to 28 Weeks
Eligibility Inclusion Criteria: - Birth between 23-26 W for Phase II, between 23-28 W for Phase III - Post natal age < 12 hours - Parental or Legal Authority Consent - Parents with a social security or health insurance (if applicable according to the local regulation) Exclusion Criteria: - Birth defect / Congenital anomaly - Twin-to-twin transfusion syndrome not cured - Suspicion of pulmonary hypoplasia - Suspicion of hepatic impairment (hemorrhagic syndrome and/or severe hypoglycemia) - Clinical instability that can lead to rapid death - Impossibility to start treatment before 12 hours of life - Parents placed under judicial protection - Participation in other clinical trial using acetaminophen during the first 5 days of life, indomethacin or ibuprofen during the first 3 days of life or using rescue treatment of PDA not recommended in the TREOCAPA trial

Study Design


Intervention

Drug:
Acetaminophen
In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses). In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II.
NACL 0.9%
In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses). In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II.

Locations

Country Name City State
Belgium Centre Hospitalier Universitaire de Liège Liège
Denmark The Juliane Marie Centre, Rigshospitalet, Copenhagen University hospital Copenhagen
Estonia East Tallinn Central Hospital Tallinn
Estonia Tallinn Children's Hospital Tallinn
Estonia Tartu University Hospital, Neonatal and Paediatric Intensive Care Unit Tartu
Finland Helsinki University Hospital, Department of Children and Adolecents, Neonatology Helsinki
Finland Kuopio University Hospital, Department of Pediatrics Kuopio
Finland Oulu University Hospital, Department of Pediatrics Oulu
Finland Tampere University Hospital, Department of Pediatrics Tampere
Finland Turku University Hospital, Department of Peadiatrics Turku
France CHU Angers Angers
France Hopital Jeanne de Flandre Lille
France Hôpital Croix-Rousse Lyon
France Hospice civils de Lyon, Hopital Femme Enfant Lyon
France Hôpital de la conception Marseille
France Hôpital Marseille Nord Marseille
France Hôpital Arnaud de Villeneuve, Département de Pédiatrie Néonatale et Réanimation Pédiatrique Montpellier
France CHU Nantes, Hopital mére Enfant Nantes
France CENTRE hospitalier intercommunal de Creteil Paris
France Hopital Cochin, Service de Médecine et Réanimation néonatales de Port-Royal Paris
France Hôpital Necker - Enfants malades Paris
France Hopital Robert Debré, Néonatologie Paris
France CHU Rennes, Hopital Sud Rennes
France CHU Strasbourg, Hôpital de Hautepierre Strasbourg
France Centre Hospitalo-Universitaire de Toulouse Toulouse
France CHRU de Tours Tours
Hungary Bács Kiskun COUNTY HOSPITAL Kecskemét
Ireland Cork University Hospital Cork
Italy Azienda Ospedaliero - Universitaria delle Marche Ancona
Norway Oslo University Hospital Oslo
Portugal Centro Hospitalar Universitário Lisboa Norte, EPE -Hospital Santa Maria Lisboa
Portugal Centro Hospitalar e Universitário do Porto, EPE - Centro Materno Infantil do Norte Porto
Sweden Karolinska University Hospital Solna
Switzerland Hopital Universitaire de Geneve (HUG) - Hopital des enfants Geneva
Switzerland University Children's Hospital Lausanne Lausanne
Switzerland University Hospital of Zürich Zürich

Sponsors (5)

Lead Sponsor Collaborator
Institut National de la Santé Et de la Recherche Médicale, France Connect for Children, European Fundation for the Care of the Newborn Infants, PARTNERS for International clinical Research, UPCET

Countries where clinical trial is conducted

Belgium,  Denmark,  Estonia,  Finland,  France,  Hungary,  Ireland,  Italy,  Norway,  Portugal,  Sweden,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Closure of Ductus Arteriosus (Primary endpoint of phase II) Number of participants with closed Ductus Arteriosus (DA) assessed by echocardiography during the first 7 days of life, defined as DA closed at two consecutive echocardiographies or if the DA is closed at echocardiography of Day 7 Day 7
Primary The survival without severe morbidity (Primary endpoint of phase III) the survival without severe morbidity at 36 weeks of post menstrual age or at first discharge home, whichever comes first. The severe morbidities include bronchopulmonary dysplasia (BPD Grade 3 according to NIH consensus), necrotizing enterocolitis (NEC) of Bell's stage II or III, intraventricular hemorrhage (IVH) grade III-IV or cystic leukomalacia observed at any time up to 36 weeks of post menstrual age Up to 36 weeks of post menstrual age
Secondary Analgesia/sedation drugs consumption during first week after birth (Secondary endpoint of phase III) Number of days during the first week the infants received sedation/analgesia treatment Day 7
Secondary Closure of Ductus arteriosus (Secondary endpoint of phase III) Number of patients with a closed Ductus Arteriosus (DA) assessed by echocardiography at Day 7- Day 10 Day 7
Secondary Number of back-up treatment of PDA (Secondary endpoint of phase III) Number of the patients receiving back-up treatment At 36 weeks of Post menstrual age
Secondary Number of days during the first week after birth with catecholamines administration (Secondary endpoint of phase III) Number of days during the first week the infants received catecholamines in perfusion Day 7
Secondary Early pulmonary hemorrhage (Secondary endpoint of phase III) Number of infants with early pulmonary hemorrhage Day 7
Secondary Blood acetaminophen levels in extrem preterm infant (Secondary endpoint of Phase II and Phase III) Analysis of acetaminophen levels according to the administered dose and the time of sample collection Day 7
Secondary Toxicity of Acetaminophen in extrem preterm infant (Secondary endpoint of Phase II and Phase III) Number of patient with increase of AST/ALT more than 2 times the normal value (according to local standards) or the first AST/ALT dosage before loading dose of Acetaminophen if if available in standard care Day 7
See also
  Status Clinical Trial Phase
Recruiting NCT05134116 - SafeBoosC III Two-year Follow-up
Active, not recruiting NCT03714633 - Stockholm Preterm Interaction-Based Intervention N/A
Not yet recruiting NCT05490173 - The Pilot Experimental Study of the Neuroprotective Effects of Exosomes in Extremely Low Birth Weight Infants N/A
Completed NCT03649282 - HFNC and NCPAP in Extremely Preterm Infants N/A
Completed NCT01773902 - Protein for Premies N/A
Completed NCT04121897 - Therapist Education and Massage for Parent Infant-Outcomes N/A
Recruiting NCT04413097 - Delayed Cord Clamping With Oxygen In Extremely Low Gestation Infants N/A
Recruiting NCT05265195 - PeriviAble DeLiveries: ALIgning PArental aNd PhysiCian PrioritiEs (ALLIANCE)
Completed NCT05686252 - RCT: The Effect of Held Position During Kangaroo Care on Physiological Parameters of Premature Infants N/A
Recruiting NCT06027645 - Early Intervention Based on Neonatal Crawling in Very Premature Infants at Risk For Neurodevelopmental Disorder N/A
Completed NCT04074525 - Evaluating Decisional Regret Among Mothers
Completed NCT05152875 - Relationship Between Fungal Colonization and Severe Bronchopulmonary Dysplasia
Completed NCT02782637 - Prenatal Counseling in Extreme Prematurity: Parents' View N/A
Recruiting NCT04715373 - LISA in the Delivery Room for Extremely Preterm Infants N/A
Not yet recruiting NCT05334550 - Effectiveness of Home Based Early Intervention of Extremely Premature Infant by Parent N/A
Not yet recruiting NCT06220461 - Folic Acid Supplementation to Reduce Anemia in Extremely Preterm Infants N/A
Recruiting NCT05248477 - Improve the Survival Without Morbidity of Extremely Preterm Infants (PREMEX) N/A
Completed NCT04652063 - Osteopathic Manipulative Medicine to Reduce Developmental Delays N/A
Completed NCT04256889 - Use Of Nfant(R) Technology Feeding System For Infants Less Than 30 Weeks GA N/A
Not yet recruiting NCT03786497 - Protecting Brains and Saving Futures - the PBSF Protocol